Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: Analysis of PAOLA-1/ENGOT-ov25 phase III trial.
暂无分享，去创建一个
K. Yonemori | I. Vergote | I. Ray-Coquard | G. Scambia | F. Joly | M. Mirza | M. Demarchi | A. Burges | S. Chabaud | E. Pujade-Lauraine | J. Kurtz | C. Guillemet | A. Anota | I. Tsibulak | C. Cropet | N. Laínez | M. Lapresa | C. Pisano | E. Ortega Izquierdo | Beyhan Atasevan | Carmen Pisano | Eugenia Ortega Izquierdo